Jaume Alijotas Reig Instituciones de las que forman parte Jefe de grupo Enfermedades Sistémicas Vall Hebron Institut de Recerca Email Jaume Alijotas Reig Email Instituciones de las que forman parte Jefe de grupo Enfermedades Sistémicas Vall Hebron Institut de Recerca
Líneas de investigación Immunologic lesional mechanisms in late adverse reactions against bioimplants. The late clinical manifestations that arise when bioimplants are applied seem to have an immunologic basis. We are studying both the histological characteristics and the lesional mechanisms of the most frequently used implants. We try to analyze the role that bacteria may have in the induction and/or maintenance of these reactions and the possible correlation between particular HLA haplotypes and the adverse effects. IP: Jaume Alijotas Reig Predictive kit to detect the possible establishment of late adverse effects related to bioimplants used in clinical practice. A high variability in the prevalence of adverse effects with an immunologic basis seems to be related with any implant used in clinical practice. We have managed to find a particular association of HLA haplotypes that increase the risk for developing these effects up to 600 times. We are nowadays working on setting up a safe and reliable biochip or kit which predicts this risk easily in a routine test. IP: Jaume Alijotas Reig Immunobiology and immunopathology of recurrent pregnancy loses and spontaneous loses. Around 2-3% of reproductive-age couples suffer recurrent pregnancy loses. Almost 18% of couples that wish to have children suffer infertility problems. Simultaneously, 2-3% of all pregnant women are diagnosed with spontaneous loses. The expression of HLA molecules, specially type G, the degree of trophoblastic apoptosis, the outsourcing of new neoantigens such as phospholipids, the balance between Th1/Th2/Th3 cytokines, the type and quantity of CD4+CD25+Foxp3+ lymphocytes, the kind and the activity of uterine NK cells (uNK) cells, the presence or absence of blocking antibodies, and other mechanisms play different roles in the achievement of the so-called "tolerant microenvironment" needed to develop a normal pregnancy. Therefore, both autoimmune and alloimmune mechanisms are important. We aim at studying which isolated, and specially associated, anomalies can be identified as risk markers to be able to evaluate possible treatments. IP: Jaume Alijotas Reig Cellular microparticles study in women with and without antiphospholipid antibodies with recurrent pregnancy loses and preeclampsia. Cellular microparticles (CMP) are released depending on the activation and/or the presence of cell apoptosis. They are capable of activating both inflammatory and coagulation pathways. It seems that levels of CMP are higher in healthy pregnant women. A working hypothesis establishes that an increase of CMP levels may be found in recurrent pregnancy loses and preeclampsia. It is thought that their thrombophilic capacity may be higher in those patients with anti-phospholipid antibodies, especially among those with lupus anticoagulant. We want to determine MPC levels in non-pregnant healthy women, pregnant women without previous abnormal obstetric events, women with recurrent pregnancy loses, and women with severe preeclampsia. We are also evaluating whether there are differences related to the presence or absence of antiphospholipid antibodies. Finally, we will also characterize the exact type of CMP (endothelial, platelet-like, leuco-monocyte, and throphoblastic). IP: Jaume Alijotas Reig Paginación Primera página « Página anterior ‹ Página 1 Página actual 2 Página 3 Siguiente página › Última página » Proyectos Factores angiogénicos durante la gestación y riesgo cardiovascular a medio-largo plazo en las pacientes con preeclampsia. Abordaje clínico y experimental. IP: Jaume Alijotas Reig Colaboradores: Manel Mendoza Cobaleda, Josep Perapoch López Entidad financiadora: Instituto de Salud Carlos III Financiación: 71995 Referencia: PI16/01997 Duración: 01/01/2017 - 31/12/2019 Incorporación del ratio sFlt1/PlGF en el diagnóstico y clasificación de preeclampsia: Ensayo clínico randomizado (EuroPE estudio) IP: Elisa Llurba Olivé Colaboradores: Jaume Alijotas Reig, Manel Mendoza Cobaleda Entidad financiadora: Instituto de Salud Carlos III Financiación: 111925 Referencia: PI16/00375 Duración: 01/01/2017 - 13/06/2017 Sulfato de magnesio en pauta continua versus discontinua en la conducta expectante de la preeclampsia grave: ensayo clínico aleatorizado IP: Anna Suy Franch Colaboradores: Jaume Alijotas Reig Entidad financiadora: Ministerio Sanidad Financiación: 57120 Referencia: EC11-474 Duración: 01/01/2012 - 31/12/2018 Sulfato de magnesio en pauta continua versus discontinua en la conducta expectante de la preeclampsia grave: ensayo clínico randomizado IP: Anna Suy Franch Colaboradores: Jaume Alijotas Reig, Maria del Mar Goya Canino Entidad financiadora: Instituto de Salud Carlos III Financiación: 62012.5 Referencia: PI11/00388 Duración: 01/01/2012 - 30/06/2016 Paginación Primera página « Página anterior ‹ Página 1 Página actual 2 Página 3 Siguiente página › Última página »
